From the Australian Associated Press
The INNA-051 nasal treatment, developed by the Australian biotech company Ena Respiratory, targets the primary site of most respiratory infections, including Covid, and activates immune defense mechanisms in the respiratory tract.
The technology could help fight coronavirus and other infections such as influenza and the common cold.
Be First to Comment